Related Experiment Videos
Facilitated percutaneous coronary intervention: is this strategy ready for implementation?
Derek P Chew1, Phil Aylward, Harvey D White
1Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92 024, Auckland 1001, New Zealand.
Current Cardiology Reports
|July 1, 2005
Summary
Pharmacologic fibrinolysis reduces mortality in ST-elevation myocardial infarction (STEMI) but has limitations. Facilitated percutaneous coronary intervention (PCI) may offer a hybrid approach to improve patient outcomes.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Reperfusion therapy is crucial for acute ST-elevation myocardial infarction (STEMI).
- Pharmacologic fibrinolysis significantly reduces STEMI mortality but has limitations.
- Current strategies like primary percutaneous coronary intervention (PCI) face logistic challenges.
Purpose of the Study:
- To explore the potential of a hybrid strategy combining pharmacologic reperfusion with PCI for STEMI.
- To evaluate if facilitated PCI can extend the benefits of myocardial reperfusion to more patients.
Main Methods:
- Review of existing literature on reperfusion therapies for STEMI.
- Analysis of limitations of fibrinolysis and primary PCI.
- Discussion of the proposed hybrid strategy and facilitated PCI.
Main Results:
- Attempts to improve fibrinolysis or combine it with other agents have not improved mortality.
- Prehospital fibrinolysis and primary PCI reduce mortality but have logistic constraints.
- Facilitated PCI is a potential hybrid strategy for broader reperfusion benefits.
Conclusions:
- A hybrid strategy combining pharmacologic reperfusion with PCI is attractive for STEMI management.
- Ongoing large-scale trials will define the true benefit of facilitated PCI.
- Effective implementation requires careful consideration of clinical practice determinants if trials are positive.